Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.72 |
| ▸ | BTK | Q06187 | 16/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16716426 | 0.93 | BTK (0.62) | SYKBTKAURKA | |
| SCHEMBL1068125 | 0.92 | BTK (0.62) | SYKBTKAURKA | |
| SCHEMBL1066572 | 0.91 | BTK (0.61) | SYKBTKAURKA | |
| SCHEMBL12962408 | 0.90 | BTK (0.60) | SYKBTKAURKA | |
| SCHEMBL1066039 | 0.90 | BTK (0.60) | SYKBTKAURKA | |
| SCHEMBL1066489 | 0.90 | BTK (0.60) | SYKBTKAURKA | |
| SCHEMBL12637975 | 0.90 | BTK (0.60) | SYKBTKAURKA | |
| SCHEMBL1068097 | 0.90 | BTK (0.59) | SYKBTKAURKA | |
| SCHEMBL1068181 | 0.89 | BTK (0.58) | SYKBTKAURKA | |
| SCHEMBL1068183 | 0.89 | BTK (0.58) | SYKBTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | claimed |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | claimed |
| WO-2005047290-A2 | IMIDAZO[1,2-A] PYRAZIN-8-YLAMINES AS KINASE INHIBITORS | CELLULAR GENOMICS INC. (US) | 2005-05-26 | — | — | WO | claimed |
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2270200-A2 | Kinase inhibitors, and methods of using and identifying kinase inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270200-A2 | Kinase inhibitors, and methods of using and identifying kinase inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1812442-A2 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005047290-A2 | IMIDAZO[1,2-A] PYRAZIN-8-YLAMINES AS KINASE INHIBITORS | CELLULAR GENOMICS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | SYK 4/4885BTK 1/4885AURKA 261/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | SYK 2/4885BTK 1/4885AURKA 632/4885 |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | BTK, SYK, LCK | SYK 2/4885BTK 1/4885AURKA 407/4885 |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, MAP3K1, PRKACA | SYK 483/4885BTK 477/4885AURKA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.